Literature DB >> 16785999

Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas.

D Vitagliano1, G Portella, G Troncone, A Francione, C Rossi, A Bruno, A Giorgini, S Coluzzi, T C Nappi, J L Rothstein, R Pasquinelli, G Chiappetta, D Terracciano, V Macchia, R M Melillo, A Fusco, M Santoro.   

Abstract

Ras oncogenes are frequently mutated in thyroid carcinomas. To verify the role played by N-ras in thyroid carcinogenesis, we generated transgenic mice in which a human N-ras(Gln61Lys) oncogene (Tg-N-ras) was expressed in the thyroid follicular cells. Tg-N-ras mice developed thyroid follicular neoplasms; 11% developed follicular adenomas and approximately 40% developed invasive follicular carcinomas, in some cases with a mixed papillary/follicular morphology. About 25% of the Tg-N-ras carcinomas displayed large, poorly differentiated areas, featuring vascular invasion and forming lung, bone or liver distant metastases. N-ras(Gln61Lys) expression in cultured PC Cl 3 thyrocytes induced thyroid-stimulating hormone-independent proliferation and genomic instability with micronuclei formation and centrosome amplification. These findings support the notion that mutated ras oncogenes could be able to drive the formation of thyroid tumors that can progress to poorly differentiated, metastatic carcinomas.

Entities:  

Mesh:

Year:  2006        PMID: 16785999     DOI: 10.1038/sj.onc.1209527

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

Review 1.  Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Authors:  James A Fagin; Nicholas Mitsiades
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-12       Impact factor: 4.690

2.  Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.

Authors:  Alyaksandr V Nikitski; Susan L Rominski; Vincenzo Condello; Cihan Kaya; Mamta Wankhede; Federica Panebianco; Hong Yang; Daniel L Altschuler; Yuri E Nikiforov
Journal:  Thyroid       Date:  2019-08-16       Impact factor: 6.568

3.  An essential role for Pax8 in the transcriptional regulation of cadherin-16 in thyroid cells.

Authors:  Tiziana de Cristofaro; Tina Di Palma; Imma Fichera; Valeria Lucci; Luca Parrillo; Mario De Felice; Mariastella Zannini
Journal:  Mol Endocrinol       Date:  2011-12-01

Review 4.  Modulation of sodium iodide symporter in thyroid cancer.

Authors:  Aparna Lakshmanan; Daniel Scarberry; Daniel H Shen; Sissy M Jhiang
Journal:  Horm Cancer       Date:  2014-09-19       Impact factor: 3.869

Review 5.  Lessons from mouse models of thyroid cancer.

Authors:  Caroline S Kim; Xuguang Zhu
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

6.  Animal models of cancer in the head and neck region.

Authors:  Seungwon Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2009-06-27       Impact factor: 3.372

7.  Thyroid cancer: current molecular perspectives.

Authors:  Francesca Giusti; Alberto Falchetti; Francesco Franceschelli; Francesca Marini; Annalisa Tanini; Maria Luisa Brandi
Journal:  J Oncol       Date:  2010-03-29       Impact factor: 4.375

8.  Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.

Authors:  V G Antico-Arciuch; M Dima; X-H Liao; S Refetoff; A Di Cristofano
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

Review 9.  Modeling thyroid cancer in the mouse.

Authors:  X-G Zhu; S-Y Cheng
Journal:  Horm Metab Res       Date:  2009-04-08       Impact factor: 2.936

10.  Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.

Authors:  Kelly A Miller; Nicole Yeager; Kristen Baker; Xiao-Hui Liao; Samuel Refetoff; Antonio Di Cristofano
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.